nogrЭкспериментальная и клиническая гастроэнтерологияExperimental and Clinical Gastroenterology1682-8658«Global Media Technologies»10.31146/1682-8658-ecg-230-10-171-177nogr-3015Research ArticleОБЗОРREVIEWСаркопения ассоциированная с заболеваниями печени и желчевыводящих путейSarcopenia associated with liver diseases and biliary tracthttps://orcid.org/0000-0001-9421-9545СадретдиноваЛ. Д.SadretdinovaL. D.shuraleyka1@mail.ruhttps://orcid.org/0000-0002-7217-7222ГанцеваХ. Х.GantsevaH. H.noemail@neicon.ruhttps://orcid.org/0000-0001-5965-2108АхияроваК. Э.AkhiyarovaK. E.noemail@neicon.ruhttps://orcid.org/0000-0002-1287-814XХафизовМ. М.KhafizovM. M.noemail@neicon.ruhttps://orcid.org/0000-0002-0841-3024ТюринА. В.TyurinA. V.noemail@neicon.ruФедеральное государственное бюджетное образовательное учреждение высшего образования Башкирский государственный медицинский университет Министерства здравоохранения РоссииРоссияBashkir State Medical University of the Ministry of Health of RussiaRussian Federation202410122024010171177Copyright © Садретдинова Л.Д., Ганцева Х.Х., Ахиярова К.Э., Хафизов М.М., Тюрин А.В., 20242024Садретдинова Л.Д., Ганцева Х.Х., Ахиярова К.Э., Хафизов М.М., Тюрин А.В.Sadretdinova L.D., Gantseva H.H., Akhiyarova K.E., Khafizov M.M., Tyurin A.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nogr.org/jour/article/view/3015

Саркопения считается первичной, когда она связана с возрастом, и вторичной, когда она связана с заболеваниями. Уменьшение массы скелетных мышц при возрастной саркопении происходит постепенно и имеет гендерную дифференциацию: более выражена у мужчин, чем у женщин. Установлено, что потеря массы скелетных мышц составляет приблизительно 5% за 10 лет у пожилых людей. При саркопении, связанной с заболеванием, скорость потери массы скелетных мышц не следует линейному тренду: процент потери мышечной массы превышает уровень, отмеченный при возрастной саркопении, и увеличивается экспоненциально на поздних этапах заболевания. Саркопения, возникающая в результате заболеваний печени, является одним из примеров формирования вторичной саркопении. Целью данного обзора является представление актуальных данных литературы, которые касаются взаимосвязи между саркопенией и заболеваниями печени, с учетом особенностей патогенеза, клинической картины и способов диагностики.

Sarcopenia is considered primary when it is associated with age, and secondary when it is associated with diseases. The decrease in skeletal muscle mass during age-related sarcopenia occurs gradually and has gender differentiation: it is more pronounced in men than in women. Skeletal muscle mass loss has been found to be approximately 5% over 10 years in older adults. In disease-associated sarcopenia, the rate of skeletal muscle mass loss does not follow a linear trend: the percentage of muscle mass loss exceeds the level noted in age-related sarcopenia and increases exponentially in later stages of the disease. Sarcopenia resulting from liver disease is one example of the formation of secondary sarcopenia. The purpose of this review is to present current literature data on the relationship between sarcopenia and liver diseases, taking into account the characteristics of pathogenesis, clinical presentation and diagnostic methods. The purpose of this review is to present current literature data regarding the relationship between sarcopenia and liver diseases, taking into account the characteristics of pathogenesis, clinical picture and diagnostic methods.

саркопениясаркопеническое ожирениеметаболически ассоциированная жировая болезнь печенихронические заболевания печениsarcopeniasarcopenic obesitymetabolically associated fatty liver diseasechronic liver diseasesReferencesRosenberg I.H. Summary comments: epidemiological and methodological problems in determining nutritional status of older persons. Am J Clin Nutr. 1989;50: 1231-1233. doi: 10.1093/ajcn/50.5.1231.Rosenberg I.H. Summary comments: epidemiological and methodological problems in determining nutritional status of older persons. Am J Clin Nutr. 1989;50: 1231-1233. doi: 10.1093/ajcn/50.5.1231.Sayer A.A., Syddall H., Martin H. et al. The developmental origins of sarcopenia. J Nutr Health Aging. 2008; 12: 427-32.Sayer A.A., Syddall H., Martin H. et al. The developmental origins of sarcopenia. J Nutr Health Aging. 2008; 12: 427-32.Dodds R.M., Syddall H.E., Cooper R. et al. Grip strength across the life course: normative data from twelve British studies. PLoS One. 2014; 9: e113637.Dodds R.M., Syddall H.E., Cooper R. et al. Grip strength across the life course: normative data from twelve British studies. PLoS One. 2014; 9: e113637.Sayer A.A., Cruz-Jentoft A. Sarcopenia definition, diagnosis and treatment: consensus is growing. Age Ageing. 2022 Oct 6; 51(10): afac220. doi: 10.1093/ageing/afac220.Sayer A.A., Cruz-Jentoft A. Sarcopenia definition, diagnosis and treatment: consensus is growing. Age Ageing. 2022 Oct 6; 51(10): afac220. doi: 10.1093/ageing/afac220.Pleshchev I.E., Achkasov E.E., Nikolenko V.N., Shkrebko A.N. Sarcopenia: modern approaches to diagnostics and rehabilitation. 2022;(1):66-66. (in Russ.) doi: 10.17513/spno.31443.@@ Плещёв И.Е., Ачкасов Е.Е., Николенко В.Н., Шкребко А.Н. Саркопения: современные подходы к диагностике и реабилитации // Современные проблемы науки и образования. 2022;(1):66-66. doi: 10.17513/spno.31443.Pleshchev I.E., Achkasov E.E., Nikolenko V.N., Shkrebko A.N. Sarcopenia: modern approaches to diagnostics and rehabilitation. 2022;(1):66-66. (in Russ.) doi: 10.17513/spno.31443.@@ Плещёв И.Е., Ачкасов Е.Е., Николенко В.Н., Шкребко А.Н. Саркопения: современные подходы к диагностике и реабилитации // Современные проблемы науки и образования. 2022;(1):66-66. doi: 10.17513/spno.31443.Petermann-Rocha F., Balntzi V., Gray S.R., Lara J., Ho F.K., Pell J.P., Celis-Morales C. Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2022 Feb; 13(1):86-99. doi: 10.1002/jcsm.12783.Petermann-Rocha F., Balntzi V., Gray S.R., Lara J., Ho F.K., Pell J.P., Celis-Morales C. Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2022 Feb; 13(1):86-99. doi: 10.1002/jcsm.12783.Xiong L., Liao T., Guo T. et al. The relationship between sarcopenia and mortality in Chinese community-dwelling adults: a 7-year cohort study with propensity score matching and Mendelian randomization. Front Endocrinol (Lausanne). 2023 Oct 4; 14:1215512. doi: 10.3389/fendo.2023.1215512.Xiong L., Liao T., Guo T. et al. The relationship between sarcopenia and mortality in Chinese community-dwelling adults: a 7-year cohort study with propensity score matching and Mendelian randomization. Front Endocrinol (Lausanne). 2023 Oct 4; 14:1215512. doi: 10.3389/fendo.2023.1215512.Larsson L., Degens H., Li M., Salviati L., Lee Y.I., Thompson W., Kirkland J.L., Sandri M. Sarcopenia: Aging-Related Loss of Muscle Mass and Function. Physiol. Rev. 2019; 99:427-511. doi: 10.1152/physrev.00061.Larsson L., Degens H., Li M., Salviati L., Lee Y.I., Thompson W., Kirkland J.L., Sandri M. Sarcopenia: Aging-Related Loss of Muscle Mass and Function. Physiol. Rev. 2019; 99:427-511. doi: 10.1152/physrev.00061.Kizilarslanoglu M.C., Kuyumcu M.E., Yesil Y., Halil M. Sarcopenia in critically ill patients. J. Anesth. 2016; 30:884-890. doi: 10.1007/s00540-016-2211-4.Kizilarslanoglu M.C., Kuyumcu M.E., Yesil Y., Halil M. Sarcopenia in critically ill patients. J. Anesth. 2016; 30:884-890. doi: 10.1007/s00540-016-2211-4.Cespiati A., Meroni M., Lombardi R., Oberti G., Dongiovanni P., Fracanzani A.L. Impact of Sarcopenia and Myosteatosis in Non-Cirrhotic Stages of Liver Diseases: Similarities and Differences across Aetiologies and Possible Therapeutic Strategies. Biomedicines. 2022 Jan 16; 10(1):182. doi: 10.3390/biomedicines10010182.Cespiati A., Meroni M., Lombardi R., Oberti G., Dongiovanni P., Fracanzani A.L. Impact of Sarcopenia and Myosteatosis in Non-Cirrhotic Stages of Liver Diseases: Similarities and Differences across Aetiologies and Possible Therapeutic Strategies. Biomedicines. 2022 Jan 16; 10(1):182. doi: 10.3390/biomedicines10010182.Maev I.V., Andreev D.N., Kucheryavyy Yu.A. Metabolically associated fatty liver disease - a disease of the 21st century: A review. Consilium Medicum. 2022;24(5):325-332. doi: 10.26442/20751753.2022.5.201532.@@ Маев И.В., Андреев Д.Н., Кучерявый Ю.А. Метаболически ассоциированная жировая болезнь печени - заболевание XXI века. Consilium Medicum. 2022; 24(5):325-332. doi: 10.26442/20751753.2022.5.201532.Maev I.V., Andreev D.N., Kucheryavyy Yu.A. Metabolically associated fatty liver disease - a disease of the 21st century: A review. Consilium Medicum. 2022;24(5):325-332. doi: 10.26442/20751753.2022.5.201532.@@ Маев И.В., Андреев Д.Н., Кучерявый Ю.А. Метаболически ассоциированная жировая болезнь печени - заболевание XXI века. Consilium Medicum. 2022; 24(5):325-332. doi: 10.26442/20751753.2022.5.201532.Eslam M., Newsome P.N., Sarin S.K. et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J. Hepatol. 2020; 73:202-209. doi: 10.1016/j.jhep.2020.03.039.Eslam M., Newsome P.N., Sarin S.K. et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J. Hepatol. 2020; 73:202-209. doi: 10.1016/j.jhep.2020.03.039.Wijarnpreecha K., Kim D., Raymond P., Scribani M., Ahmed A. Associations between sarcopenia and nonalcoholic fatty liver disease and advanced fibrosis in the USA. Eur. J. Gastroenterol. Hepatol. 2019; 31:1121-1128. doi: 10.1097/MEG.0000000000001397.Wijarnpreecha K., Kim D., Raymond P., Scribani M., Ahmed A. Associations between sarcopenia and nonalcoholic fatty liver disease and advanced fibrosis in the USA. Eur. J. Gastroenterol. Hepatol. 2019; 31:1121-1128. doi: 10.1097/MEG.0000000000001397.Kim G., Lee S.E., Lee Y.B. et al. Relationship Between Relative Skeletal Muscle Mass and Nonalcoholic Fatty Liver Disease: A 7-Year Longitudinal Study. Hepatology. 2018; 68:1755-1768. doi: 10.1002/hep.30049.Kim G., Lee S.E., Lee Y.B. et al. Relationship Between Relative Skeletal Muscle Mass and Nonalcoholic Fatty Liver Disease: A 7-Year Longitudinal Study. Hepatology. 2018; 68:1755-1768. doi: 10.1002/hep.30049.Chan W.K., Chuah K.H., Rajaram R.B., Lim L.L., Ratnasingam J., Vethakkan S.R. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review. J Obes Metab Syndr. 2023; 32:197-213.Chan W.K., Chuah K.H., Rajaram R.B., Lim L.L., Ratnasingam J., Vethakkan S.R. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review. J Obes Metab Syndr. 2023; 32:197-213.Mansouri A., Gattolliat C.-H., Asselach T. Mitochondrial Dysfunction and Signaling in Chronic Liver Diseases. Gastroenterology. 2018; 155:629-647. doi: 10.1053/j.gastro.2018.06.083.Mansouri A., Gattolliat C.-H., Asselach T. Mitochondrial Dysfunction and Signaling in Chronic Liver Diseases. Gastroenterology. 2018; 155:629-647. doi: 10.1053/j.gastro.2018.06.083.Saklayen M.G. The global epidemic of the metabolic syndrome. Curr. Hypertens. Rep. 2018; 20:12. doi: 10.1007/s11906-018-0812-z.Saklayen M.G. The global epidemic of the metabolic syndrome. Curr. Hypertens. Rep. 2018; 20:12. doi: 10.1007/s11906-018-0812-z.Saklayen M.G. The global epidemic of the metabolic syndrome. Curr. Hypertens. Rep. 2018; 20:12. doi: 10.1007/s11906-018-0812-z.Saklayen M.G. The global epidemic of the metabolic syndrome. Curr. Hypertens. Rep. 2018; 20:12. doi: 10.1007/s11906-018-0812-z.Baczek J., Silkiewicz M., Wojszel Z.B. Myostatin as a biomarker of muscle wasting and other pathologies-state of the art and knowledge gaps. Nutrients. 2020; 12:2401. doi: 10.3390/nu12082401.Baczek J., Silkiewicz M., Wojszel Z.B. Myostatin as a biomarker of muscle wasting and other pathologies-state of the art and knowledge gaps. Nutrients. 2020; 12:2401. doi: 10.3390/nu12082401.Kalyani R.R., Corriere M., Ferrucci L. Age-related and disease-related muscle loss: the effect of diabetes, obesity, and other diseases. The Lancet Diabetes & Endocrinology. 2014; 2(10):819-829. doi: 10.1016/S2213-8587(14)70034-8.Kalyani R.R., Corriere M., Ferrucci L. Age-related and disease-related muscle loss: the effect of diabetes, obesity, and other diseases. The Lancet Diabetes & Endocrinology. 2014; 2(10):819-829. doi: 10.1016/S2213-8587(14)70034-8.Zhang H.J., Zhang X.F., Ma Z.M. et al. Irisin is inversely associated with intrahepatic triglyceride contents in obese adults. J Hepatol. 2013; 59:557-562.Zhang H.J., Zhang X.F., Ma Z.M. et al. Irisin is inversely associated with intrahepatic triglyceride contents in obese adults. J Hepatol. 2013; 59:557-562.Lumeng C.N., Bodzin J.L., Saltiel A.R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117:175-84. doi: 10.1172/jci29881.Lumeng C.N., Bodzin J.L., Saltiel A.R. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117:175-84. doi: 10.1172/jci29881.Sheptulina A.F., Dzhioeva O.N., Drapkina O.M. Sarcopenia and non-alcoholic fatty liver disease: shared pathogenesis mechanisms as possible targets of therapy and prevention.Russian Journal of Preventive Medicine. 2021;24(4):57-62. (In Russ.) doi: 10.17116/profmed20212404157.@@ Шептулина А.Ф., Джиоева О.Н., Драпкина О.М. Саркопения и неалкогольная жировая болезнь печени: общие патогенетические механизмы как возможные мишени терапии и профилактики. Профилактическая медицина. 2021; 24(4):57-62. doi: 10.17116/profmed20212404157.Sheptulina A.F., Dzhioeva O.N., Drapkina O.M. Sarcopenia and non-alcoholic fatty liver disease: shared pathogenesis mechanisms as possible targets of therapy and prevention.Russian Journal of Preventive Medicine. 2021;24(4):57-62. (In Russ.) doi: 10.17116/profmed20212404157.@@ Шептулина А.Ф., Джиоева О.Н., Драпкина О.М. Саркопения и неалкогольная жировая болезнь печени: общие патогенетические механизмы как возможные мишени терапии и профилактики. Профилактическая медицина. 2021; 24(4):57-62. doi: 10.17116/profmed20212404157.Zambon Azevedo V., Silaghi C.A., Maurel T., Silaghi H., Ratziu V., Pais R. Impact of Sarcopenia on the Severity of the Liver Damage in Patients With Non-alcoholic Fatty Liver Disease. Front Nutr. 2022 Jan 17; 8:774030. doi: 10.3389/fnut.2021.774030.Zambon Azevedo V., Silaghi C.A., Maurel T., Silaghi H., Ratziu V., Pais R. Impact of Sarcopenia on the Severity of the Liver Damage in Patients With Non-alcoholic Fatty Liver Disease. Front Nutr. 2022 Jan 17; 8:774030. doi: 10.3389/fnut.2021.774030.Donini L.M., Busetto L., Bauer J.M. et al. Critical appraisal of definitions and diagnostic criteria for sarcopenic obesity based on a systematic review. Clin Nutr. 2020; 39:2368-2388.Donini L.M., Busetto L., Bauer J.M. et al. Critical appraisal of definitions and diagnostic criteria for sarcopenic obesity based on a systematic review. Clin Nutr. 2020; 39:2368-2388.Hong H.C., Hwang S.Y., Choi H.Y. et al. Relationship between sarcopenia and nonalcoholic fatty liver disease: The Korean sarcopenic obesity study. Hepatology. 2014; 59(5):1772-1778. doi: 10.1002/hep.26716.Hong H.C., Hwang S.Y., Choi H.Y. et al. Relationship between sarcopenia and nonalcoholic fatty liver disease: The Korean sarcopenic obesity study. Hepatology. 2014; 59(5):1772-1778. doi: 10.1002/hep.26716.Wijarnpreecha K., Kim D., Raymond P., Scribani M., Ahmed A. Associations between sarcopenia and nonalcoholic fatty liver disease and advanced fibrosis in the USA. European Journal of Gastroenterology & Hepatology. 2019; 31(9):1121-1128. doi: 10.1097/MEG.0000000000001397.Wijarnpreecha K., Kim D., Raymond P., Scribani M., Ahmed A. Associations between sarcopenia and nonalcoholic fatty liver disease and advanced fibrosis in the USA. European Journal of Gastroenterology & Hepatology. 2019; 31(9):1121-1128. doi: 10.1097/MEG.0000000000001397.Ma J., Hwang S.-J., McMahon G.M. et al. Mid-adulthood cardiometabolic risk factor profiles of sarcopenic obesity. Obesity. 2016; 24:526-534. doi: 10.1002/oby.21356.Ma J., Hwang S.-J., McMahon G.M. et al. Mid-adulthood cardiometabolic risk factor profiles of sarcopenic obesity. Obesity. 2016; 24:526-534. doi: 10.1002/oby.21356.Talwalkar J.A., Souto E., Jorgensen R.A., Lindor K.D. Natural history of pruritus in primary biliary cirrhosis. Clin Gastroenterol Hepatol. 2003;(1):297-302. doi: 10.1016/S1542-3565(03)00134-4.Talwalkar J.A., Souto E., Jorgensen R.A., Lindor K.D. Natural history of pruritus in primary biliary cirrhosis. Clin Gastroenterol Hepatol. 2003;(1):297-302. doi: 10.1016/S1542-3565(03)00134-4.Qiu J., Thapaliya S., Runkana A. et al. Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-κB-mediated mechanism. Proc Natl Acad Sci USA. 2013;(110):18162-7. doi: 10.1073/pnas.1317049110.Qiu J., Thapaliya S., Runkana A. et al. Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-κB-mediated mechanism. Proc Natl Acad Sci USA. 2013;(110):18162-7. doi: 10.1073/pnas.1317049110.Davuluri G., Krokowski D., Guan B.J. et al. Metabolic adaptation of skeletal muscle to hyperammonemia drives the beneficial effects of l-leucine in cirrhosis. J Hepatol. 2016;(65):929-37. doi: 10.1016/j.jhep.2016.06.004.Davuluri G., Krokowski D., Guan B.J. et al. Metabolic adaptation of skeletal muscle to hyperammonemia drives the beneficial effects of l-leucine in cirrhosis. J Hepatol. 2016;(65):929-37. doi: 10.1016/j.jhep.2016.06.004.Myazin R.G. Sarcopenia and non-alcoholic fatty liver disease. Experimental and Clinical Gastroenterology. 2024;(2):120-130. (In Russ.) doi: 10.31146/1682-8658-ecg-222-2-120-130.@@ Мязин Р.Г. Саркопения и неалкогольная жировая болезнь печени. Экспериментальная и клиническая гастроэнтерология.2024; 222 (2): 120-130. doi: 10.31146/1682-8658-ecg-222-2-120-130.Myazin R.G. Sarcopenia and non-alcoholic fatty liver disease. Experimental and Clinical Gastroenterology. 2024;(2):120-130. (In Russ.) doi: 10.31146/1682-8658-ecg-222-2-120-130.@@ Мязин Р.Г. Саркопения и неалкогольная жировая болезнь печени. Экспериментальная и клиническая гастроэнтерология.2024; 222 (2): 120-130. doi: 10.31146/1682-8658-ecg-222-2-120-130.Dasarathy S., Merli M. Sarcopenia from mechanism to diagnosis and treatment in liver disease. J Hepatol. 2016;(65):1232-44. doi: 10.1016/j.jhep.2016.07.040.Dasarathy S., Merli M. Sarcopenia from mechanism to diagnosis and treatment in liver disease. J Hepatol. 2016;(65):1232-44. doi: 10.1016/j.jhep.2016.07.040.Muñoz-Cánoves P., Scheele C., Pedersen B.K., Serrano A.L.Interleukin-6 myokine signaling in skeletal muscle: a double-edged sword? FEBS J. 2013;(280):4131-48. doi: 10.1111/febs.12338.Muñoz-Cánoves P., Scheele C., Pedersen B.K., Serrano A.L.Interleukin-6 myokine signaling in skeletal muscle: a double-edged sword? FEBS J. 2013;(280):4131-48. doi: 10.1111/febs.12338.Maev I.V., Reshetnyak V.I. Pathophysiology of Trophic Disorders in Primary Biliary Cholangitis. Effective Pharmacotherapy. 2022; 18 (22): 46-61. (in Russ.) doi: 10.33978/2307-3586-2022-18-22-46-61.@@ Маев И.В., Решетняк В.И. Патофизиология трофологических нарушений при первичном билиарном холангите. Эффективная фармакотерапия. 2022; 18 (22): 46-61. doi: 10.33978/2307-3586-2022-18-22-46-61.Maev I.V., Reshetnyak V.I. Pathophysiology of Trophic Disorders in Primary Biliary Cholangitis. Effective Pharmacotherapy. 2022; 18 (22): 46-61. (in Russ.) doi: 10.33978/2307-3586-2022-18-22-46-61.@@ Маев И.В., Решетняк В.И. Патофизиология трофологических нарушений при первичном билиарном холангите. Эффективная фармакотерапия. 2022; 18 (22): 46-61. doi: 10.33978/2307-3586-2022-18-22-46-61.Saeki C., Oikawa T., Kanai T. et al. Relationship between osteoporosis, sarcopenia, vertebral fracture, and osteosarcopenia in patients with primary biliary cholangitis. Eur J Gastroenterol Hepatol. 2021;(33):731-7. doi: 10.1097/MEG.0000000000001791.Saeki C., Oikawa T., Kanai T. et al. Relationship between osteoporosis, sarcopenia, vertebral fracture, and osteosarcopenia in patients with primary biliary cholangitis. Eur J Gastroenterol Hepatol. 2021;(33):731-7. doi: 10.1097/MEG.0000000000001791.Tsochatzis E.A., Bosch J., Burroughs A.K. Liver cirrhosis. Lancet. 2014;(383):1749-1761.Tsochatzis E.A., Bosch J., Burroughs A.K. Liver cirrhosis. Lancet. 2014;(383):1749-1761.Abdelbasset W.K., Nambi G., Elsayed S.H. et al. Prevalence and nonpharmacological interventions for sarcopenia among cirrhotic patients. Dis. Markers. 2021; 2021:8866093. doi: 10.1155/2021/8866093.Abdelbasset W.K., Nambi G., Elsayed S.H. et al. Prevalence and nonpharmacological interventions for sarcopenia among cirrhotic patients. Dis. Markers. 2021; 2021:8866093. doi: 10.1155/2021/8866093.Kurmaev D.P., Bulgakova S.V., Treneva E.V., Pervyshin N.A., Sharonova L.A., Dolgikh Yu.A. Malnutrition, dysfunction of the gastrointestinal tract and sarcopenia - features of combined pathology. Experimental and Clinical Gastroenterology. 2024;(2):111-119. (In Russ.) doi: 10.31146/1682-8658-ecg-222-2-111-119.@@ Курмаев Д.П., Булгакова С.В., Тренева Е.В., Первышин Н.А., Шаронова Л.А., Долгих Ю.А. Мальнутриция, нарушение функции желудочно-кишечного тракта и саркопения - особенности сочетанной патологии. Экспериментальная и клиническая гастроэнтерология. 2024;(2):111-119. doi: 10.31146/1682-8658-ecg-222-2-111-119.Kurmaev D.P., Bulgakova S.V., Treneva E.V., Pervyshin N.A., Sharonova L.A., Dolgikh Yu.A. Malnutrition, dysfunction of the gastrointestinal tract and sarcopenia - features of combined pathology. Experimental and Clinical Gastroenterology. 2024;(2):111-119. (In Russ.) doi: 10.31146/1682-8658-ecg-222-2-111-119.@@ Курмаев Д.П., Булгакова С.В., Тренева Е.В., Первышин Н.А., Шаронова Л.А., Долгих Ю.А. Мальнутриция, нарушение функции желудочно-кишечного тракта и саркопения - особенности сочетанной патологии. Экспериментальная и клиническая гастроэнтерология. 2024;(2):111-119. doi: 10.31146/1682-8658-ecg-222-2-111-119.Lee J.H., Cho A.R., Lee Y.J. Relationship between serum alkaline phosphatase and low muscle mass index among Korean adults: A nationwide population-based study. Biomolecules. 2021; 11(6):842. doi: 10.3390/biom11060842.Lee J.H., Cho A.R., Lee Y.J. Relationship between serum alkaline phosphatase and low muscle mass index among Korean adults: A nationwide population-based study. Biomolecules. 2021; 11(6):842. doi: 10.3390/biom11060842.Xiao L., Dai M., Zhao F. et al. Assessing the risk factors associated with sarcopenia in patients with liver cirrhosis: a case-control study. Sci Rep. 2023 Dec 9; 13(1):21845. doi: 10.1038/s41598-023-48955-z.Xiao L., Dai M., Zhao F. et al. Assessing the risk factors associated with sarcopenia in patients with liver cirrhosis: a case-control study. Sci Rep. 2023 Dec 9; 13(1):21845. doi: 10.1038/s41598-023-48955-z.Nishikawa H., et al. Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria. Hepatol. Res. 2016; 46:951-963.Nishikawa H., et al. Japan Society of Hepatology guidelines for sarcopenia in liver disease (1st edition): Recommendation from the working group for creation of sarcopenia assessment criteria. Hepatol. Res. 2016; 46:951-963.Boström P. et al. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012; 481:463-468.Boström P. et al. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012; 481:463-468.Zhao M., Zhou X., Yuan C., Li R., Ma Y., Tang X. Association between serum irisin concentrations and sarcopenia in patients with liver cirrhosis: a cross-sectional study. Sci Rep. 2020 Sep 30; 10(1):16093. doi: 10.1038/s41598-020-73176-z.Zhao M., Zhou X., Yuan C., Li R., Ma Y., Tang X. Association between serum irisin concentrations and sarcopenia in patients with liver cirrhosis: a cross-sectional study. Sci Rep. 2020 Sep 30; 10(1):16093. doi: 10.1038/s41598-020-73176-z.Zeng X., Shi Z.W., Yu J.J. et al. Sarcopenia as a prognostic predictor of liver cirrhosis: a multicentre study in China. J Cachexia Sarcopenia Muscle. 2021 Dec; 12(6):1948-1958. doi: 10.1002/jcsm.12797.Zeng X., Shi Z.W., Yu J.J. et al. Sarcopenia as a prognostic predictor of liver cirrhosis: a multicentre study in China. J Cachexia Sarcopenia Muscle. 2021 Dec; 12(6):1948-1958. doi: 10.1002/jcsm.12797.Nadinskaia M. Yu., Maevskaya M.V., Bakulin I.G. et al. Diagnostic and Prognostic Value of Hyperammonemia in Patients with Liver Cirrhosis, Hepatic Encephalopathy, and Sarcopenia (Experts’ Agreement).Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2024;34(1):85-100. doi: 10.22416/1382-4376-2024-34-1-85-100.@@ Надинская М.Ю., Маевская М.В., Бакулин И.Г. и др. Диагностическое и прогностическое значение гипераммониемии у пациентов с циррозом печени, печеночной энцефалопатией и саркопенией (соглашение специалистов). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2024; 34(1):85-100. doi: 10.22416/1382-4376-2024-34-1-85-100.Nadinskaia M. Yu., Maevskaya M.V., Bakulin I.G. et al. Diagnostic and Prognostic Value of Hyperammonemia in Patients with Liver Cirrhosis, Hepatic Encephalopathy, and Sarcopenia (Experts’ Agreement).Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2024;34(1):85-100. doi: 10.22416/1382-4376-2024-34-1-85-100.@@ Надинская М.Ю., Маевская М.В., Бакулин И.Г. и др. Диагностическое и прогностическое значение гипераммониемии у пациентов с циррозом печени, печеночной энцефалопатией и саркопенией (соглашение специалистов). Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2024; 34(1):85-100. doi: 10.22416/1382-4376-2024-34-1-85-100.Saeki C., Kanai T., Nakano M., Oikawa T., Torisu Y., Saruta M., Tsubota A. Low Serum 25-Hydroxyvitamin D Levels Are Related to Frailty and Sarcopenia in Patients with Chronic Liver Disease. Nutrients. 2020 Dec 12; 12(12):3810. doi: 10.3390/nu12123810.Saeki C., Kanai T., Nakano M., Oikawa T., Torisu Y., Saruta M., Tsubota A. Low Serum 25-Hydroxyvitamin D Levels Are Related to Frailty and Sarcopenia in Patients with Chronic Liver Disease. Nutrients. 2020 Dec 12; 12(12):3810. doi: 10.3390/nu12123810.DiMartini A., Cruz R.J., Dew M.A. et al. Muscle mass predicts outcomes following liver transplantation. Liver Transpl. 2013; 19:1172-1180.DiMartini A., Cruz R.J., Dew M.A. et al. Muscle mass predicts outcomes following liver transplantation. Liver Transpl. 2013; 19:1172-1180.Rezende I.F.B., Conceição-Machado M.E.P., Souza V.S., Santos E.M.D., Silva L.R. Sarcopenia in children and adolescents with chronic liver disease. J Pediatr (Rio J). 2020 Jul-Aug; 96(4):439-446. doi: 10.1016/j.jped.2019.02.005.Rezende I.F.B., Conceição-Machado M.E.P., Souza V.S., Santos E.M.D., Silva L.R. Sarcopenia in children and adolescents with chronic liver disease. J Pediatr (Rio J). 2020 Jul-Aug; 96(4):439-446. doi: 10.1016/j.jped.2019.02.005.Mazeaud S., Zupo R., Couret A., Panza F., Sardone R., Castellana F. Prevalence of Sarcopenia in Liver Cirrhosis: A Systematic Review and Meta-Analysis. Clin Transl Gastroenterol. 2023 Jul 1; 14(7): e00584. doi: 10.14309/ctg.0000000000000584.Mazeaud S., Zupo R., Couret A., Panza F., Sardone R., Castellana F. Prevalence of Sarcopenia in Liver Cirrhosis: A Systematic Review and Meta-Analysis. Clin Transl Gastroenterol. 2023 Jul 1; 14(7): e00584. doi: 10.14309/ctg.0000000000000584.Montano-Loza A.J., Meza-Junco J., Prado C.M. et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol. 2012; 10:166-173, 173.e1.Montano-Loza A.J., Meza-Junco J., Prado C.M. et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol. 2012; 10:166-173, 173.e1.Montano-Loza A.J., Duarte-Rojo A., Meza-Junco J. et al. Inclusion of sarcopenia within MELD (MELD-sarcopenia) and the prediction of mortality in patients with cirrhosis. Clin Transl Gastroenterol. 2015; 6: e102.Montano-Loza A.J., Duarte-Rojo A., Meza-Junco J. et al. Inclusion of sarcopenia within MELD (MELD-sarcopenia) and the prediction of mortality in patients with cirrhosis. Clin Transl Gastroenterol. 2015; 6: e102.Salimov U.R., Stoma I.O., Fedoruk D.A., Kovalev A.A., Scherba A.E., Rummo O.O. Sarcopenia in chronic liver disease, can we predict complications? Transplantologiya. The Russian Journal of Transplantation. 2022;14(4):408-420. doi: 10.23873/2074-0506-2022-14-4-408-420.@@ Салимов У.Р., Стома И.О., Федорук Д.А., Ковалев А.А., Щерба А.Е., Руммо О.О. Саркопения хронических болезней печени. Можем ли мы предвидеть осложнения? Трансплантология. 2022; 14(4):408-420. doi: 10.23873/2074-0506-2022-14-4-408-420.Salimov U.R., Stoma I.O., Fedoruk D.A., Kovalev A.A., Scherba A.E., Rummo O.O. Sarcopenia in chronic liver disease, can we predict complications? Transplantologiya. The Russian Journal of Transplantation. 2022;14(4):408-420. doi: 10.23873/2074-0506-2022-14-4-408-420.@@ Салимов У.Р., Стома И.О., Федорук Д.А., Ковалев А.А., Щерба А.Е., Руммо О.О. Саркопения хронических болезней печени. Можем ли мы предвидеть осложнения? Трансплантология. 2022; 14(4):408-420. doi: 10.23873/2074-0506-2022-14-4-408-420.Topan M.M., Sporea I., Dănilă M., Popescu A., Ghiuchici A.M., Lupuşoru R., Şirli R. Impact of sarcopenia on survival and clinical outcomes in patients with liver cirrhosis. Front. Nutr. 2021; 8:766451. doi: 10.3389/fnut.2021.766451.Topan M.M., Sporea I., Dănilă M., Popescu A., Ghiuchici A.M., Lupuşoru R., Şirli R. Impact of sarcopenia on survival and clinical outcomes in patients with liver cirrhosis. Front. Nutr. 2021; 8:766451. doi: 10.3389/fnut.2021.766451.Dajti E., Renzulli M., Ravaioli F. et al. The interplay between sarcopenia and portal hypertension predicts ascites and mortality in cirrhosis. Dig. Liver Dis. 2023; 55:637-643. doi: 10.1016/j.dld.2022.11.011.Dajti E., Renzulli M., Ravaioli F. et al. The interplay between sarcopenia and portal hypertension predicts ascites and mortality in cirrhosis. Dig. Liver Dis. 2023; 55:637-643. doi: 10.1016/j.dld.2022.11.011.

The authors declare that there are no conflicts of interest present.